

# REAL-WORLD PATIENT USE AND PERCEPTION, SATISFACTION, AND ADHERENCE WITH A CALCIPOTRIOL AND BETAMETHASONE DIPROPIONATE PAD-CREAM FOR THE TREATMENT OF PLAQUE PSORIASIS

José Luis López Estebarez<sup>1</sup>, Hjalmar Kurzen<sup>2</sup>, Marta Menéndez<sup>1</sup>, Giulia Greta Dradi<sup>1</sup>, Jordi Galván<sup>3</sup>

<sup>1</sup> Dermatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

<sup>2</sup> Technische Universität München, Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Munich, Germany.

<sup>3</sup> Global Medical Affairs Department, Almirall SA, Barcelona, Spain.

## INTRODUCTION

- Psoriasis detrimentally impacts patients' quality of life (QoL), even on those with a mild form of the disease.<sup>1</sup>
- Topical agents successfully treat 70-80% of patients with mild-to-moderate psoriasis.<sup>1</sup>
- An aqueous cream of calcipotriol (CAL) and betamethasone dipropionate (BDP) based on polyaphron dispersion (PAD) technology is a first-line option in the topical treatment of psoriasis, with demonstrated efficacy, high convenience, and favorable safety and tolerability.<sup>2</sup>
- Since patient dissatisfaction and non-adherence are major barriers to treatment success<sup>1</sup>, the objective of this study was to assess patients' perception, as well as their satisfaction and adherence with CAL/BDP PAD cream in a real-world setting.

## METHODS

- Between 12<sup>th</sup> September and 14<sup>th</sup> November 2023, patients from Spain and Germany with plaque psoriasis (with or without psoriatic arthritis) who were currently using (78%) or had used within the past 3 months (33%) CAL/BDP PAD cream for a period longer than 2 weeks were identified.
- Patients were offered to participate in a 10-minute online survey. The questionnaire consisted of 30 questions on their demographic and clinical characteristics, the CAL/BDP PAD cream use, and its perception, satisfaction, and adherence.
- All patients agreed to voluntarily participate in this survey and provided their informed consent before answering any question.
- Per design, this survey did not affect the treatment of the patients, which was performed according to routine clinical practice.

## RESULTS

### Demographic and clinical characteristics

- A total of 129 patients with plaque psoriasis from Spain and Germany completed the survey. The demographic and clinical characteristics are shown in **Table 1**.
- The 98% of patients had their QoL impacted and the 40% very impacted.

**Table 1. Demographic and clinical characteristics**

Characteristic	N=129
Age (years), mean (SD)	43.1 (12.9)
Female, n (%)	85 (65.9)
Country, n (%)	
Spain	86 (66.7)
Germany	43 (33.3)
Type of psoriasis, n (%)	
Cutaneous psoriasis	103 (79.8)
Cutaneous psoriasis + Psoriatic arthritis	26 (20.2)
Years since psoriasis diagnosis, mean (SD)	12.2 (11.3)
Percentage of BSA, mean (SD)	10.9 (15.4)
Affected body areas*, n (%)	
Scalp	82 (63.6)
Ears	39 (30.2)
Face	27 (20.9)
Elbows	75 (58.1)
Hands	41 (31.8)
Knees	52 (40.3)
Feet	35 (27.1)
Other areas of the legs	37 (28.7)
Back	31 (24.0)

\*Only those body areas that are affected in >20% of patients are shown. BSA, body surface area; SD, standard deviation.


### Use of CAL/BDP PAD cream

- The 45% of patients used the product for their body and scalp psoriasis, 44% for their body only and 11% for their scalp only.
- The 47% of patients applied CAL/BDP PAD cream once daily, 9% less than once a day, 32% twice a day and 12% more than 3 times a day.
- The mean treatment duration was 14 weeks.
- The 58% of patients reported waiting ≤10 minutes before getting dressed, with an average waiting time of 15 minutes.


### Satisfaction and adherence with CAL/BDP PAD cream

- Most patients (93%) showed satisfaction with CAL/BDP PAD cream (**Figure 1**) and 49% showed high satisfaction.
- The 66% of patients reported high adherence through a visual analogue scale (VAS), that is, scored the VAS between 80 and 100 (**Figure 2**).

**Figure 1. Satisfaction of patients with CAL/BDP PAD cream**




**Figure 2. Adherence assessed through a visual analogue scale (VAS)**



### Perception of CAL/BDP PAD cream

- The top three factors for the choice of a topical treatment for psoriasis, applied to CAL/BDP PAD-cream, were "easy/convenient to apply", "well tolerated" and "does not cause itching/burning" (**Figure 3**).
- Furthermore, the 91% of patients preferred CAL/BDP PAD cream compared to their previous topical treatments. Most found it more effective, easier to use, and with fewer side effects (**Figure 4**).

**Figure 3. Percentage of patients who rated the selection factors with a score of 8 to 10, when applied to CAL/BDP PAD cream**



Note: In the survey, patients could rate each factor with a score ranging from 0 ("do not agree at all") to 10 ("completely agree").

**Figure 4. CAL/BDP PAD cream compared to previous topical treatments**



## CONCLUSIONS

- Patients with plaque psoriasis treated with CAL/BDP PAD cream show high treatment satisfaction and good adherence to it. They highlight its ease/convenience of use, tolerability, rapid onset of action and positive impact on their personal appearance and self-esteem.

## REFERENCES

- Pinter A, et al. *J Eur Acad Dermatol Venereol.* 2023;37 Suppl 1:3-8.
- Torres T, et al. *Dermatol Ther (Heidelb).* 2023;13(10):2153-69.

## ACKNOWLEDGEMENTS

TFS HealthScience provided support in the preparation of this poster. This analysis was funded by Almirall.

